Author:
Nauck Michael,Wilhelm Birgit
Publisher
Springer Science and Business Media LLC
Reference35 articles.
1. Ahmann A, Rodbard HW, Rosenstock J, et al; NN2211-3917 Study Group. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2015; 17(11): 1056–1064.
2. Balena R, Hensley IE, Miller S, Barnett AH. Combination therapy with GLP-1 receptor agonists and basal insulins: a systematic review of the literature. Diabetes Obes Metab 2013; 15: 485–502.
3. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Therapie des Typ-2-Diabetes — Kurzfassung, 1. Auflage. Version 4. 2013, zuletzt geändert: November 2014. Abrufbar unter:
www.dm-therapie.versorgungsleitlinien.de
(aufgerufen am 20.1.2016).
4. Buse JB, Bergenstal RM, Glass LC, et al. Use of twicedaily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2011; 154: 103–112.
5. Diamant M, Nauck MA, Shaginian R, et al; for the 4B Study Group. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in diabetes. Diabetes Care 2014; 37(10): 2763–2773.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献